News Shortcuts from other journals

FDA considers curbing use of erythropoietins for patients with cancer

BMJ 2007; 334 doi: (Published 21 June 2007) Cite this as: BMJ 2007;334:1297

The controversy surrounding overuse of synthetic erythropoietins in the US has shifted lately to patients with cancer, who are given these agents for the anaemia associated with chemotherapy. While treatment helps patients avoid blood transfusions, the potential risks include thromboembolism (already seen in patients …

View Full Text

Log in

Log in through your institution


* For online subscription